HepVu

An estimated 3.5 million people in the U.S. are living with chronic Hepatitis C infection.

Home Local Data Oklahoma

Local Data: Oklahoma

There are approximately 53,300 people living with Hepatitis C in Oklahoma.

Oklahoma

Hepatitis C Prevalence

Estimated number of people living with Hepatitis C, 2013-2016 53,300

Estimated rate of people living with Hepatitis C per 100,000 population, 2013-2016 1,820

Estimated percent of people living with Hepatitis C, by Sex, 2013-2016

66.0% 34.0%
  • Male
  • Female

Estimated percent of people living with Hepatitis C, by Race/Ethnicity, 2013-2016

9.9% 90.1%
  • Black
  • Non-Black

Estimated percent of people living with Hepatitis C, by Age, 2013-2016

1.9% 72.0% 26.0%
  • Less than 50
  • 50-74 (Baby Boomer)
  • 75 and above

Estimated rate of people living with Hepatitis C per 100,000 population, by Geography, 2013-2016

2000 1600 1200 800 400 0 1,820.0 State 1,008.2 Region 926.5 United States

Hepatitis C Mortality

Number of deaths related to Hepatitis C, 2017 555

Rate of deaths related to Hepatitis C per 100,000 population, 2017 14

Percent of deaths of people related to Hepatitis C, by Sex, 2017

67.6% 32.4%
  • Male
  • Female

Percent of deaths of people related to Hepatitis C, by Race/Ethnicity, 2017

15.1% 11.0% 73.0% 0.9%
  • American Indian or Alaska Native, Asian or Pacific Islander, or Hispanic/Latinx
  • Black
  • White
  • Data suppressed or not available

Percent of deaths of people related to Hepatitis C, by Age, 2017

12.8% 80.4% 3.4% 3.4%
  • Less than 50
  • 50-74 (Baby Boomer)
  • 75 and above
  • Data suppressed or not available

Number of deaths related to Hepatitis C, 2013-2017

2013 2014 2015 2016 2017 400 500 600 422 523 510 538 555

Rate of deaths related to Hepatitis C per 100,000 population, by Geography, 2017

100 80 60 40 20 0 14.0 State 5.9 Region 5.3 United States

Demographics, 2017

Total Population 3,930,864

State Population By Age

  • Less than 50 (66.1%)
  • 50-74 (Baby Boomer) (27.5%)
  • 75 and above (6.4%)

Hepatitis C, by Age

Estimated Percent of People Living with Hepatitis C, by Age, 2013-2016

Percent of Deaths Related to Hepatitis C, by Age, 2017

  • Less than 50
  • 50-74 (Baby Boomer)
  • 75 and above
  • Data suppressed or not available

Opioid Indicators

Opioid Prescription Rate, 2020 59.3

Pain Reliever Misuse Percent, 2019-2020 3.6

Social Determinants of Health, 2018

  • State
  • Region
  • United States
87.8% 86.2% 87.5%

Percent of Population with a High School Education, 2018

0.465 0.484 0.481

Income Inequality (Gini Coefficient), 2018

16.1% 15.4% 14.0%

Percent of Population Living in Poverty, 2018

$49,204 $52,678 $59,039

Median Household Income, 2018

16.0% 13.6% 8.6%

Percent of Population Lacking Health Insurance, 2018

Viral Hepatitis Treatment Restrictions

Prior Authorization

State Medicaid programs may require patients to receive prior authorization in order to receive treatment for Hepatitis C.

PA Required PA Removed

Fibrosis Level Treatment Restrictions

State Medicaid programs may require a patient to reach a certain stage of fibrosis (liver scarring) before being able to access treatment for Hepatitis C.

F3 F2 F1 No Restrictions

Substance Use Treatment Restrictions

State Medicaid programs may require a period of abstinence from drugs or alcohol prior to or during treatment or require providers to counsel their patients regarding drug or alcohol use before being able to access treatment for Hepatitis C.

6 Months 3 Months Abstinence Screening and Counseling No Restrictions

Prescriber Treatment Restrictions

State Medicaid programs may require training or for a specialist to be involved for a prescription for Hepatitis C treatment.

By or in Consultation with Specialist Prescriber Training or Certification No Restrictions

Retreatment Restrictions

State Medicaid programs may require more severe restrictions for patients seeking retreatment for Hepatitis C.

Retreatment Restrictions No Restrictions

Statuses of state Medicaid restrictions are as of August 2023. Source: CHLPI and NVHR.

Sign up for HepVu updates.